Edgen Stock·Oct 20 2025, 07:49Back
Gilead Sciences’ Trodelvy Achieves Significant Progress-Free Survival in First-Line mTNBC Study
Edgen Stock·Oct 20 2025, 07:49
[1] Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study (https://finance.yahoo.com/news/trodelvy-reduc ...)[2] Gilead Sciences' Phase 3 ASCENT-03 Study: A Pivotal Moment for Long-Term Growth? (https://vertexaisearch.cloud.google.com/groun ...)[3] Trodelvy Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study - Gilead Sciences (https://vertexaisearch.cloud.google.com/groun ...)
